News

A high rate of response to neoadjuvant PD-1 blockade in patients with desmoplastic melanoma suggests such therapy could reduce the extent of surgery needed on the face and neck.

SWOG researchers have used methylation patterns in cell-free DNA from blood samples to predict which patients with muscle-invasive bladder cancer are likely to benefit from neoadjuvant chemo and which patients can safely skip it.

Adding standing physician orders to electronic record systems did not improve adherence to guidelines for prophylactic prescribing of colony-stimulating factors for febrile neutropenia for patients on high-risk or low-risk chemotherapy.

Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma

Survival data from the first prospective, randomized biomarker validation trial in muscle-invasive bladder cancer presented at GU ASCO

Higher toxicity risk for women was known for chemotherapy, now also identified for immunotherapy and targeted therapy

Major financial hardship common after cancer diagnosis, despite insurance

Combo with immunotherapy drug can be effective in patients who are not good candidates for chemo